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Abstract
Introduction
Brain/Computer Interaction (BCI) devices are designed to alter neural signals and, thereby,
mental activity. This study was a randomized, waitlist (TAU) controlled trial of a BCI, EEG
neurofeedback training (NF), in patients with chronic PTSD to explore the capacity of NF to
reduce PTSD symptoms and increase affect regulation capacities.
Study Design
52 individuals with chronic PTSD were randomized to either NF (n = 28) or waitlist (WL) (n =
24). They completed four evaluations, at baseline (T1), after week 6 (T2), at post-treatment
(T3), and at one month follow up (T4). Assessment measures were:1. Traumatic Events
Screening Inventory (T1); 2. the Clinician Administered PTSD Scale (CAPS; T1, T3, T4);
3. the Davidson Trauma Scale (DTS; T1-T4) and 4. the Inventory of Altered Self-Capacities
(IASC; T1-T4). NF training occurred two times per week for 12 weeks and involved a se-
quential placement with T4 as the active site, P4 as the reference site.
Results
Participants had experienced an average of 9.29 (SD = 2.90) different traumatic events. Post-
treatment a significantly smaller proportion of NF (6/22, 27.3%) met criteria for PTSD than
the WL condition (15/22, 68.2%), χ2 (n = 44, df = 1) = 7.38, p = .007. There was a significant
treatment condition x time interaction (b = -10.45, t = -5.10, p< .001). Measures of tension
reduction activities, affect dysregulation, and affect instability exhibited a significant Time x
Condition interaction. The effect sizes of NF (d = -2.33 within, d = - 1.71 between groups) are
comparable to those reported for the most effective evidence based treatments for PTSD.
Discussion
Compared with the control group NF produced significant PTSD symptom improvement in
individuals with chronic PTSD, as well as in affect regulation capacities. NF deserves further
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investigation for its potential to ameliorate PTSD and to improve affect regulation, and to
clarify its mechanisms of action.
Scientific background and rationale
The potential of brain-computer interaction devices (BCI) to alter neural signals and associ-
ated mental activity makes them strong candidates to emerge as a new generation of psychiat-
ric interventions [1]. BCIs utilize fMRI or EEG as information about brain activity and
provide visual and/or auditory feedback to alter neural activity. Thus far, most BCI research
has focused on helping physically disabled users communicate commands, such as stimulation
of muscles in paralyzed individuals and in stroke rehabilitation [2].
However, a wide variety of BCIs are currently being explored for performance enhance-
ment, mental focus and tranquility [3]. EEG neurofeedback (NF) training represents one of
the earliest applications of BCIs, and even though it has been in use for about three decades
with well documented effects in over 2000 peer reviewed scientific publications, serious ques-
tions remain about its clinical utility and the validity and scientific rigor of extant research [4].
NF is thought to indirectly modify behavior by changing neuronal activation or connectiv-
ity patterns in the CNS via operant conditioning. NF has been shown to be able to reshape
neural activity, as measured by electroencephalogram (EEG) frequency components [5–7] and
fMRI [8–11]. NF research has focused mainly on performance enhancement (e.g. [12]) and on
clinical conditions such as Attention Deficit Hyperactivity Disorder (ADHD)[13–16]. A few
studies have investigated its potential in the treatment of depression[17,18], substance abuse
[19], and posttraumatic stress disorder (PTSD)[20–22].
In NF training, neural activity is recorded from scalp electrodes and fed back in real time to
subjects in a readily understood, visual format (simple computer games). NF associated EEG
changes have been correlated with changes in various functional outcomes, including cortico-
motor excitability, memory, cognition, sleep, and mood, as well as increases in affect regula-
tion and executive function, sustained attention, and working memory [23–25].
Specific objectives
NF training may help individuals with PTSD acquire self-regulation skills by stabilizing EEG
activity, and thereby improve focus and attention. The objective of this study was to investigate
whether NF could substantially alter affect regulation capacities, and thereby improve PTSD
symptomatology. This is particularly important because recovery from PTSD depends on
being able to manage intense arousal [26]. Impaired affect regulation is a major cause of dis-
continuation of exposure-based PTSD treatments [27–29]. Improving affect regulation has
been shown to 1) reduce the severity of PTSD symptoms, 2) decrease risk behaviors (e.g. sui-
cidal and self-injurious behaviors, substance use) and 3) make subsequent exposure therapy
more effective [30,31]. EEG markers of PTSD disordered arousal include increased cortical
activation (manifested in reduced alpha activity) and increased theta/alpha ratio [32–34].
Brain activity in the alpha-1 band has been linked to attentional processes [35,36], while theta
power has been linked to working memory performance [37,38], both of which are impaired
in PTSD [26]. A recent study examining potential mechanisms for NF’s effects on PTSD found
alterations in arousal (i.e., an increased sense of calm) correlated with changes in intrinsic net-
work connectivity and alpha oscillations [21].
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Study Design
This randomized, waitlist-controlled trial evaluated the efficacy of NF to increase affect regula-
tion and reduce PTSD symptoms in adults with multiple trauma exposures and treatment
resistant PTSD (i.e., having received six or more months of trauma focused therapy without
sustained self-reported clinical improvement).
Study Sample
Following IRB review by the Justice Resource Institute Institutional Review Board and specific
approval by that IRB of all aspects of the study, adults 18–58 years old with treatment non-
responsive PTSD were recruited via newspaper and radio ads, the Trauma Center website
(www.traumacenter.org), and solicitation from mental health professionals. The study was
conducted between July 1, 2012 and July 1, 2015. Eligible subjects signed the IRB approved
consent form that spelled out procedures, risks and benefits of the study. Trauma history was
obtained by self-report ad scored on the Traumatic Events Screening Inventory [39], an
18-item self-report measure assessing lifetime occurrence of both acute (e.g. accident, natural
disaster, loss) and interpersonal (e.g. neglect, separation, physical / sexual / emotional abuse,
domestic violence) forms of trauma. Individuals were eligible if they met DSM-IV criteria for
PTSD per the Clinician Administered PTSD Scale (CAPS) [40], and had received weekly
trauma-focused psychotherapy for a minimum of six months. After completion of all initial
evaluations subjects were randomly assigned by a computer generated randomization program
to either 12 weeks of twice weekly NF or a waitlist (WL) control condition. Both groups were
required to continue all ongoing treatments (psychotherapeutic and pharmacological) and to
refrain from making changes in their current treatment regimens for the duration of this
study. Participants in the WL condition were provided 24 NF sessions free of charge after the
time 3 (week 12) follow-up evaluation.
Exclusion criteria included: unstable medical condition; receiving disability benefits; active
suicide risk or life-threatening self-mutilation; psychotic or bipolar disorder; traumatic brain
injury (TBI); history of seizures; current substance or alcohol abuse; ongoing traumatic expo-
sure (such as domestic violence); changing ongoing treatment during the course of the study;
Global Assessment of Functioning (GAF) score<40.
Of the 52 subjects in the ITT sample, 26 (50%) were on psychotropic mediation 21 (40%)
were not, and 5 (10%) had missing data. A breakdown of medication rates and types for each
group were as follows: waitlist control; 10 subjects on medication (41.7% of waitlist group)
with 6 subjects (25%) on SSRIs, 3 subjects (12.5%) on benzodiazepines, 2 subjects (8.3%) on
antianxiety, 2 subjects (8.3%) on buproprion, 2 subjects (8.3%) on an SSNRI, and 1 subject
(4.2%) on a tricyclic antidepressant. Active NFB; 16 subjects on medication (57.1% of NF
group), with 7 subjects (25%) on SSRIs, 4 subjects (14.3%) on stimulants, 3 subjects (10.7%) on
antipsychotics, 5 subjects (17.8%) on benzodiazepines, and 3 subjects (10.7%) on buproprion.
Evaluation Procedures
All data were collected and analyzed at the Trauma Center @ JRI. After providing informed
consent participants completed four evaluations assessing psychological and behavioral func-
tioning: at study baseline, at week 6 (i.e., session 12 of NF if in active treatment condition), 12
weeks (session 24 -post-treatment) and week 16 (one month follow up). The participants were
compensated $25 for baseline and week 6 evaluations, $35 for week 12 evaluations, and $50 for
1-month follow-ups, totaling $135 for NF participants and $245 for WL participants who com-
pleted all evaluations. Evaluators were post-doctoral and master’s level clinicians who received
training and ongoing supervision in administration of study measures. Inter-rater reliability on
Neurofeedback for PTSD
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the CAPS was established at 80% agreement. Strenuous efforts were made to keep evaluators
blind to treatment condition, though in one case the blinding was inadvertently compromised.
NF Intervention Procedures
The NF system utilized EEGer neurofeedback software manufactured by EEG Spectrum Inter-
national Education and Research, Inc. The system utilized a Procomp2 amplifier manufac-
tured by Thought Technology LTD. The lowpass filtering is provided by the EEGer software.
The training sites were fixed for all participants, and involved a sequential placement with T4
as the active site, P4 as the reference site, and the left ear (A1) as the ground (consistent with
previous research that demonstrates increased R temporal lobe activation in PTSD)[41,42].
Training was intended to teach subjects to alter the power spectrum of certain filtered fre-
quencies of activity; specifically, we sought to help subjects decrease the power spectrum of
slow (2–6 Hz) and fast (22–36 Hz) activity while simultaneously increasing the power spec-
trum of mid-range (10–13 Hz starting point) activity. By convention, the slow activity we
sought to decrease spans the delta and theta range and is generally associated with drowsiness
and sleep, while the fast activity is called “high beta” and is associated with high levels of mental
activation [43]. In contrast, we sought to help subjects enhance alpha activity, which is gener-
ally associated with a calm, relaxed state.
The training protocol employed standard inhibit frequencies of 2–6 HZ for slow activity
and 22–36 HZ for fast EEG activity and a beginning reward frequency of 10–13 HZ. These
spectral bands were selected based on previous research in studies of NF for PTSD [32,33],
including the results of our pilot study [22]. Subjects completed a short checklist after every
session, our internally generated “Checklist of Changes Observed After Neurofeedback Train-
ing”. Adjustment of the reward band was based on subjects’ responses to the questions on that
checklist, and followed a flexible, principle-based manual that provided rules for adjusting the
training protocol.
NF training process
NF subjects had 24 training sessions, twice weekly, each lasting up to 30 minutes. Electrodes
were applied; impedance was measured for each electrode and maintained below 10 kOhms.
After initiating the EEG measurement, subjects were asked to relax and sit quietly while a base-
line signal was obtained. Once a stable baseline signal was obtained, thresholds were set such
that the 2–6 Hz activity was over the threshold 35% of the time, 10–13 Hz (or adjusted band,
based on response) was over the threshold 65% of the time, and 22–36 Hz activity was over the
threshold 25% of the time. Subjects received auditory and visual feedback indicating reward;
specifically, auditory tones and progress in simple computer games, such as Packman or Space
Race. Feedback “rewards” (positive progress in the visual feedback videogame and tones) were
given every two seconds that the amplitude or magnitude of EEG activity in both of the inhibit
frequency bands fell below the target threshold and the amplitude or magnitude of EEG activ-
ity in the reward band exceeded the target threshold. Further adjustment of the thresholds
using the same parameters as above was made after approximately three minutes of active
training. Any other adjustments to the thresholds were limited but based on clinical judgment.
Finally, an artifact filter on the raw EEG was tailored for each subject in an effort to remove
and minimize artifact during the training (EMG, EOG, blinking, etc.). No changes were made
to the protocol except adjustments to the reward band frequency. These were made based on
rated symptoms of over-arousal (including nightmares; sleep difficulties; hyperactivity; aggres-
sive behavior, anger, anxiety; and self-reports of high arousal including self-harm, suicidal
and/or homicidal ideation), and symptoms of under-arousal (including inattention, decreased
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alertness or mental clarity; nausea; depressive symptoms; and decreased energy/fatigue) cap-
tured by the Checklist for Changes After Neurofeedback, as well as clinical judgment. If partici-
pants reported significant over-arousal symptoms for at least two training sessions, the reward
frequency was lowered by 1 Hz. This procedure was continued until the participant reported
no change, positive benefit, or symptoms of under-arousal. If the participant reported symp-
toms of under-arousal, the reward band was raised by½Hz until those symptoms remitted.
Training time started at 12 minutes; training time was raised in three-minute increments par-
ticipants reported a positive change. All but one participant achieved an endstate of thirty min-
utes per NF session.
Clinician Supervision, Fidelity, Assessment and Monitoring
NF sessions were conducted by experienced NF clinicians. Clinicians completed a session
fidelity checklist designed to mirror the specific components of each session, requiring the rat-
ing of the full, partial or unsuccessful implementation of each component, any factors that
impeded protocol adherence, and any modifications to protocol required. Changes to the
starting protocol, such as frequency adjustments, were automatically recorded by the NFB soft-
ware. Clinicians met weekly with the supervisor to review specifics of each NFB session and
individual subject logs, session fidelity checklists, and protocol adjustments. Twenty percent of
sessions were randomly selected for neurofeedback protocol review to assure that they
matched adjustments dictated by supervisory staff.
Measures
1. Clinician Administered PTSD Scale (CAPS) [40], a clinician administered interview that is
considered the gold standard for assessing PTSD, was the primary outcome measure of the
study. Each of the 17 DSM-IV-TR PTSD symptoms are assessed with regard to their frequency
and intensity over the past month using a 5-point scale (0–4). Symptoms endorsed with a fre-
quency equal to or greater than one, and an intensity of equal to or greater than two are con-
sidered to meet the minimum threshold to count as a symptom of PTSD. The CAPS can be
scored to indicate whether an individual meets the DSM criteria for a PTSD diagnoses, and
frequency and intensity items can be summed to produce a symptom severity rating that can
range from 0–136, with severity score equal to or greater than 45 necessary for a PTSD diagno-
sis. The PTSD diagnoses variable was used to evaluate inclusion criteria, while the continuous
PTSD severity score was the primary outcome for the study analyses.
2.The Davidson Trauma Scale (DTS) [44] is a self-report measure of PTSD assessing the
severity and frequency of PTSD symptoms that is structured similarly to CAPS with partici-
pants rating the frequency and severity of the 17 DSM-IV-TR PTSD symptoms using a 0–4
scale. PTSD severity scores were computed by adding all of the frequency and intensity items
of each symptom, which, like the CAPS, produces a continuous score that can range from
0–136.
3. Inventory of Altered Self-Capacities (IASC) [45] is a 63-item standardized self-report
measure consisting of seven subscales that assess the following domains of self-related psycho-
logical problems: Interpersonal Conflicts, Idealization-Disillusionment, Abandonment Con-
cerns, Identity Impairment, Susceptibility to Influence, Affect Dysregulation, and Tension
Reduction Activities. The number of items per subscale ranges from 5–9 with each item rated
using a 1 (never) to 4 (often) scale producing a continuous score for each subscale.
The CAPS, our primary outcome measure, was administered on three occasions (not mid-
point, at week 6). We included the DTS as a secondary outcome measure because it is easier to
administer; therefore, we could include it as part of the six-week assessment that occurred
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during NF-training (or the corresponding time on the waitlist). Including an additional assess-
ment increases power to detect significant results in longitudinal studies. The IASC was
administered as a secondary measure to evaluate whether NF impacted relevant emotion-regu-
lation and interpersonal processes.
Statistical Power
A post-hoc power analysis using a Monte Carlo simulation method [46] with the Mplus statis-
tical software [47] was conducted to estimate obtained power. The Monte Carlo simulation
method provides precise estimates of power for specific, hypothesized or evaluated, models
and it can adjust for the missing data patterns in the observed data [48]. We conducted the
power analysis using the estimates obtained from the multilevel growth curve models (GCMs,
described below) using the CAPS and the DTS. These power analysis indicated power esti-
mates of .56 and .77 to detect a d = .80 (usually considered the cutoff for large effect sizes) dif-
ference in change from pre-treatment to the follow-up assessment in the CAPS and DTS
severity scores, respectively, between the two treatment conditions.
Participants
After initial phone screens 71 individuals were invited for a baseline assessment. Nineteen did
not meet study criteria and were excluded: seven were on disability, six received subclinical
scores on the CAPS, two due reported ongoing domestic abuse, one suffered a substance abuse
relapse, one started another treatment, and one reported symptoms of psychosis. The remain-
ing 52 individuals were randomized to either the WL (n = 24) or NF (n = 28) conditions and
made up the intention-to-treat sample (ITT). Of the 28 individuals randomized to the NF
group, six dropped out of treatment: four after having been randomized, but before starting
the actual treatment (Fig 1). After starting NF two subjects dropped out—one had a previously
undisclosed traumatic brain injury, and one subject reported increased flashbacks. Thus, 22 of
the 28 participants assigned to NF completed the protocol. Of the 24 participants randomized
to the WL group, one withdrew consent before treatment due to a medical illness; another was
excluded after revealing that he received disability, leaving 22 participants assigned to the WL
condition who completed the protocol. A chi-squared analysis showed that there was no sig-
nificant difference between NF (6/28) and WL (2/24) ITT participants who failed to complete
the protocol conditions, χ2 (n = 52, df = 1) = 1.70, p = .192.
Table 1 presents demographic information for the entire sample and as a function of treat-
ment condition. The sample was on average middle-aged and mostly white and female. A
series of one-way ANOVAS and chi-squared tests revealed no statistically significant differ-
ences in demographic characteristics across conditions. A second series of one-way ANOVAs
and chi-squared tests were then conducted to compare the treatment completers to ITT partic-
ipants who dropped out or were excluded from the study. There was a significant difference
for only one demographic variable, marital status, χ2 (n = 48, df = 1) = 15.62, p = .004. Because
drop-outs were relatively evenly distributed across conditions, we decided not to include mari-
tal status as a co-variate.
Data Analyses
Chi-square analyses were first were used to evaluate the impact of NF on PTSD diagnoses
(present/absent). Next multilevel Growth Curve Modeling (GCM) using the mixed procedure
of the Statistical Package for the Social Sciences (SPSS [48]) examined change in PTSD symp-
toms and other study variables across the course of treatment through one-month post treat-
ment and whether these changes significantly varied across condition. Multilevel GCMs have
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become the standard for analyzing psychotherapy outcome data because of several advantages
that this approach offers (i.e., efficiency in dealing with missing observations, efficient and
powerful estimation techniques, and modeling flexibility [49]). This allowed us to include the
entire intention-to-treat sample without using data imputation procedures. Time was modeled
by including the number of weeks since baseline assessment (0, 6, 12, and 16, for pre-treat-
ment, mid-treatment, post-treatment, and one-month post-treatment assessments). Prior to
examining the impact of treatment condition on change, various unconditional change models
(examining change without predictors) were evaluated to determine the most reliable manner
to model time (e.g., linear using number of months, quadratic using number of months and
number of months squared, or non-linear using a natural-log transformation of number of
months). The best fitting change model was determined by examining the difference in the-2
Log Likelihood (i.e., deviance) estimate between competing models, which follows a chi-square
distribution. To examine the impact of treatment condition on change in outcomes, a treatment
Fig 1. Flow of participants through the trial.
doi:10.1371/journal.pone.0166752.g001
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condition dummy-coded variable was added as a predictor of change parameters (to test treat-
ment condition x time interactions). Effect sizes (d) for differences in change between condi-
tions was computed by the procedures described by Fiengold [50] producing effect size
estimates comparable to those derived from more traditional repeated measures designs (e.g.,
repeated measures ANOVA).
Table 1. Sample Demographic Information
ITT Sample
Total Waitlist Neurofeedback
(n = 52) (n = 24) (n = 28)
Age, mean (SD), y 44.40 (13.15) 42.45 (13.50) 46.04 (12.89)
Gender
Female 42 (76.2) 17 (77.3) 25 (92.6)
Male 7 (23.8) 5 (22.7) 2 (7.4)
Ethnicity
Black/African-American 4 (8.7) 2 (9.1) 2 (8.3)
Native American 1 (2.2) 1 (4.5) 0 (0.0)
White/Caucasian 35 (76.1) 15 (68.2) 20 (83.3)
Multi-Ethnic 4 (8.7) 3 (13.6) 1 (4.2)
Other 2 (4.3) 1 (4.5) 1 (4.2)
Marital Status
Married 15(31.2) 8 (36.4%) 7 (26.9)
Separated 2 (4.2) 1 (4.5) 1 (3.8)
Divorced 6 (12.5) 2 (9.1%) 4 (15.4)
Single 23 (47.9) 11 (50.0) 12 (46.2)
Widowed 2 (4.2) 0 (0.0) 2 (4.2)
Highest Level of Education
Post-Graduate 7 (14.9) 4 (18.2) 4 (16.0)
Graduate 10 (21.3) 5 (22.7) 5 (20.0)
Some Graduate 8 (17.0) 4 (18.2) 4 (16.0)
College 10 (21.3) 4 (18.2) 6 (24.0)
Some College 11 (23.4) 5 (22.7) 6 (24.0)
High school graduate 1 (2.1) 0 1 (4.0)
Employment Status
Full-Time 26 (54.2) 11 (50.0) 15 (57.7)
Part-Time 13 (27.1) 6 (27.3) 7 (26.9)
At Home Parent 2 (4.2) 1 (4.5) 1 (3.8)
Full-Time Student 2 (4.2) 1 (4.5) 1 (3.8)
Unemployed 5 (10.4) 3 (13.6) 2 (7.7)
Income
$80,000 + 9 (19.6) 6 (28.6) 2 (8.0)
$60,000 - $79,000 3 (6.5) 4 (19.0) 5 (20.0)
$40,000 - $59,000 7 (15.2) 3 (14.3) 4 (16.0)
$26,000 - $39,000 7 (15.2) 2 (9.5) 5 (20.0)
$12,000 - $25,000 9 (19.6) 0 (0.0) 3 (12.0)
less than $12,000 8 (17.4) 5 (23.8) 4 (16.0)
Declined to answer 3 (6.5) 1 (4.8) 2 (8.0)
Note: Except for Age, for which mean and standard deviation is reported, n’s with percentages in parenthesis are reported.
doi:10.1371/journal.pone.0166752.t001
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Subject Attrition and Missing Data
One of the benefits of using multilevel GCM is that we could use maximum likelihood estima-
tion, so that subject attrition and missing data did not affect the analyses as they would for less
nuanced methods. Data were screened for patterns of missingness as MLE does assume that
data is missing at random.
Results
On average participants endorsed exposure to 9.29 (SD = 2.90) of the 18 traumatic events
assessed by the TESI, which did not significantly vary as a function of condition, F (1,43) = .02,
p = .879. The most frequently endorsed events were childhood caregiver emotional abuse
(78.8%), sexual abuse (69.2%) and domestic violence, 61.5%. At baseline, all participants met
past month criteria for PTSD, and there was not a significant difference between WL (18/24,
75.0%) and NF conditions (24/27, 88.9%) meeting PTSD criteria during the past week, χ2 (n =
51, df = 1) = 1.69, p = .194. At week 12 (post-treatment) assessment, a higher proportion of
WL participants (15/22, 68.2%) met criteria for PTSD than participants receiving NF (6/22,
27.3%), χ2 (n = 44, df = 1) = 7.38, p = .007. At the week 16 (one-month post-treatment), a
higher proportion of WL participants (17/19, 90%) met criteria for PTSD in the past month
than participants receiving NF (8/19, 42%), χ2 (n = 38, df = 1) = 9.47, p = .002.
CAPS severity scores were approximately normally distributed at each time point, with the
highest skewness-to-standard-error of skewness ratio being1.91 at the post-assessment. The
unconditional change model for the CAPS severity score indicated that modeling time as the
natural-log transformation of number of weeks since baseline fit the data best accounting for
79.4% of the within-subjects variance. This pattern of change was characterized by large initial
decreases in symptoms (during treatment) that flatten out over time (during the follow-up
period). A significant treatment condition x time interaction emerged (b = -10.45, t = -5.10,
p< .001). The nature of this effect is depicted in Fig 2 with change over time and associated
effect size estimates reported in Table 2. Both the WL (d = -.62) and NF (d = -2.33) conditions
exhibited significant decreases from the pre-treatment to the second (1 month) post treatment
assessment; however, this decrease was substantially larger for the NF condition (d = -1.71).
Both groups exhibited small decreases in CAPS severity score from the first to the second post-
treatment to follow-up that did not significantly differ between conditions (d = -.16). The aver-
age decrease in CAPS score from the pre-treatment to the 1-month post treatment assessments
was 40.35 for the NF condition and 10.78 for the WL group, the former well above and the
latter well below the commonly adopted 20-point change in CAPS criteria used to indicate
clinically significant change [49]. The bottom portion of Table 2 depicts the results when
restricting the analyses to completers only and indicates that the results when using the ITT
sample or the completers only sample were virtually identical.
Estimates for the means of the self-report measures administered at pre-treatment, mid-treat-
ment, post-treatment, and at the follow-up assessments are displayed in Table 3 with the corre-
sponding change parameters depicted in Table 4. DTS scores were also approximately normally
distributed at each time point, with the highest skewness-to-standard error of skewness ration
being 3.60 at the post-treatment assessment. A linear change model best fit the data for the DTS
total score. Mirroring the CAPS severity score findings, a significant treatment condition x time
interaction emerged for the DTS (b = -1.52, t = -3.89, p< .001). The WL condition did not
exhibit a significant decrease in pre-post change in the DTS (d = -.25) while the NF condition
exhibited a significant and large decrease (d = -1.23) with a large effect size difference between
conditions (d = -.97). The analyses for the completer only sample, like for the CAPS analysis,
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was virtually identical. Therefore, we present the results for the self-report measures for only the
ITT sample.
As depicted in Table 4, four of the IASC subscales (tension reduction activities, affect dysre-
gulation total, affect skill deficits, affect instability) exhibited significant Time x Condition
interactions, with a fifth (affect instability) approaching statistical significance (p = .053). The
interpersonal conflict and identity related subscales did not exhibit significant Time x Condi-
tion interactions. The IASC subscale with the largest difference between the two conditions
Fig 2. Change in PTSD symptom severity (Total CAPS score) as a function of treatment condition. WL = waitlist, NF = Neurofeedback.
Standard Error bars included at each assessment.
doi:10.1371/journal.pone.0166752.g002
Table 2. Pre-treatment, Post-treatment, and One-Month Post-treatment CAPS levels and Change Estimates
Sample Pre Pst 1 Month Post ΔPre-1 Month Post effect-size (d)
n M (95%CI) n M (95%CI) n M (95%CI) M (95%CI) Pre-Pst(1M)
ITT WL 24 76.24 (69.13, 83.36) 22 66.49 (57.39, 75.6) 19 65.46 (55.83, 75.1) -10.78 (-19.1, -2.48) -0.62
N = 52 NF 28 79.45 (72.86, 86.04) 22 42.95 (34.1, 51.8) 19 39.1 (29.69, 48.51) -40.35 (-48.67, -32.12) -2.33
Difference 3.2 (-6.5, 12.9) -23.54 (-36.24, -10.85) -26.36 (-39.83, -12.9) -29.6 (-41.33, -17.87) -1.71
Completers WL 22 75.18 (67.84, 82.51) 22 65.68 (56.48, 74.88) 19 64.68 (54.96, 74.39) -10.5 (-18.83, -2.19) -0.61
N = 44 NF 22 80.98 (73.64, 88.31) 22 44.12 (34.92, 53.31) 19 40.23 (30.51, 49.95) -40.75 (-49.11, -32.47) -2.38
Difference 5.8 (-4.57, 16.17) -21.56 (-34.57, -8.55) -24.45 (-38.19, -10.7) -30.28 (-42.05, -18.51) -1.77
Note: WL = waitlist condition, NF = Neurofeedback condition, Pre = pre-treatment assessment, Pst = immediate post-treatment assessment, Pst (1M) =
1-month post-treatment assessment; M = mean, 95%CI = 95% Confidence Interval, d = effect size indicator with .2, .5, and .8 indicating small, medium, and
large effect sizes.
doi:10.1371/journal.pone.0166752.t002
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Table 3. Pre-treatment, Mid-Treatment, Post-treatment, and One-Month Post-treatment Means and Confidence Intervals for Self-Report Measures
Variable Condition Pre Mid Pst Pst (1M)
Est. (95%CI) Est. (95%CI) Est. (95%CI) Est. (95%CI)
Davidson Trauma Scale (DTS)
WL 62.97 (52.47, 73.48) 60.59 (51.45, 69.74) 58.21 (49.26, 67.16) 56.62 (47.09, 66.15)
NF 67.28 (57.55, 77.00) 55.74 (47.25, 64.22) 44.19 (35.76, 52.63) 36.5 (27.4, 45.6)
Difference 4.30 (-10.01, 18.62) -4.86 (-17.33, 7.62) -14.02 (-26.32, -1.72) -20.12 (-33.3, -6.95)
Difference d 0.18 -0.23 -0.66 -0.89
IASC interpersonal conflicts
WL 23.49 (21.11, 25.87) 23.04 (20.87, 25.22) 22.6 (20.23, 24.97) 22.3 (19.61, 24.98)
NF 19.22 (16.99, 21.45) 18.28 (16.21, 20.34) 17.33 (15.05, 19.62) 16.71 (14.09, 19.32)
Difference -4.27 (-7.53, -1.01) -4.77 (-7.77, -1.77) -5.26 (-8.56, -1.97) -5.59 (-9.34, -1.84)
Difference d -0.76 -0.94 -0.96 -0.90
IASC tension reduction activities
WL 17.75 (15.86, 19.63) 18.14 (16.44, 19.83) 18.26 (16.4, 20.12) 18.31 (16.35, 20.27)
NF 15.55 (13.78, 17.32) 13.25 (11.61, 14.89) 12.52 (10.70, 14.33) 12.20 (10.28, 14.12)
Difference -2.2 (-4.78, 0.39) -4.89 (-7.25, -2.53) -5.74 (-8.34, -3.14) -6.11 (-8.85, -3.37)
Difference d -0.50 -1.25 -1.35 -1.36
IASC affect dysregulation total
WL 25.14 (22.11, 28.17) 24.63 (22.03, 27.23) 24.12 (21.46, 26.78) 23.78 (20.81, 26.75)
NF 22.35 (19.5, 25.19) 20 (17.54, 22.46) 17.65 (15.08, 20.22) 16.08 (13.18, 18.99)
Difference -2.79 (-6.95, 1.36) -4.63 (-8.21, -1.05) -6.47 (-10.17, -2.77) -7.7 (-11.85, -3.54)
Difference d -0.39 -0.76 -1.04 -1.13
IASC affect skill deficits
WL 13.68 (11.69, 15.66) 13.4 (11.72, 15.09) 13.13 (11.43, 14.83) 12.95 (11.07, 14.83)
NF 12.18 (10.32, 14.04) 10.83 (9.24, 12.43) 9.49 (7.85, 11.13) 8.59 (6.76, 10.43)
Difference -1.5 (-4.22, 1.22) -2.57 (-4.89, -0.25) -3.64 (-6, -1.28) -4.35 (-6.98, -1.72)
Difference d -0.33 -0.65 -0.94 -1.04
IASC affect instability
WL 11.45 (10.00, 12.90) 11.22 (9.95, 12.49) 10.99 (9.68, 12.3) 10.84 (9.38, 12.29)
NF 10.15 (8.79, 11.51) 9.17 (7.97, 10.37) 8.18 (6.92, 9.45) 7.52 (6.10, 8.95)
Difference -1.3 (-3.29, 0.69) -2.06 (-3.80, -0.31) -2.81 (-4.63, -0.99) -3.32 (-5.35, -1.28)
Difference d -0.38 -0.68 -0.90 -0.97
IASC identity impairement total
WL 23.16 (19.77, 26.54) 22.9 (19.88, 25.92) 22.65 (19.52, 25.79) 22.48 (19.02, 25.95)
NF 21.40 (18.23, 24.58) 19.75 (16.9, 22.61) 18.1 (15.08, 21.13) 17.00 (13.62, 20.39)
Difference -1.75 (-6.39, 2.89) -3.15 (-7.31, 1.01) -4.55 (-8.91, -0.19) -5.48 (-10.32, -0.64)
Difference d -0.22 -0.44 -0.62 -0.68
IASC idealization-disillusionment
WL 19.51 (16.53, 22.49) 19.44 (16.55, 22.33) 19.37 (16.25, 22.49) 19.32 (15.89, 22.75)
NF 16.31 (13.58, 19.05) 15.12 (12.45, 17.79) 13.93 (10.99, 16.87) 13.13 (9.86, 16.40)
Difference -3.2 (-7.24, 0.84) -4.32 (-8.25, -0.39) -5.44 (-9.73, -1.15) -6.19 (-10.93, -1.45)
Difference d -0.46 -0.65 -0.75 -0.77
IASC abandonment concerns
WL 21.5 (18.28, 24.73) 21.4 (18.45, 24.36) 21.37 (18.17, 24.58) 21.36 (18.01, 24.71)
NF 20.25 (17.22, 23.28) 16.9 (14.06, 19.74) 15.83 (12.71, 18.95) 15.37 (12.09, 18.65)
Difference -1.26 (-5.68, 3.17) -4.51 (-8.61, -0.40) -5.54 (-10.01, -1.07) -5.99 (-10.68, -1.30)
Difference d -0.17 -0.65 -0.73 -0.76
IASC susceptibility to influence
(Continued )
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was tension reduction, with the NF group exhibiting significant decreases and the WL group
exhibiting slight increases. The effect size for the difference in tension reduction activities
from pre-treatment to the post-treatment assessment was -.75.
Discussion
Twenty-four sessions of NF produced significant improvements in PTSD symptomatology in
multiply traumatized individuals with PTSD who had not responded to at least six months of
trauma-focused psychotherapy, compared to a waitlist control group that continued to receive
treatment as usual. The effect sizes of NF in this study (d = -2.33 within, d = - 1.71 between
groups) is comparable to the results reported for the best evidence based treatments for PTSD:
Prolonged Exposure, CBT and EMDR, which, like this study, also generally have employed
TAU control groups, and better than any published drug intervention for PTSD [51]. The rate
of completion of the NF protocol (79%) was comparable to reported exposure-based PTSD
treatments (76%) [52]. In this study 72.7% of the NF sample no longer met criteria for PTSD.
This is comparable to the 62% reported in metanalyses of other treatment studies [53]. Only
one participant in the active treatment condition (4%) reported significant side effects, an
increase in flashbacks.
The NF subjects also had statistically significant improvements in measures of affect regula-
tion, identity impairment, abandonment concerns, and tension reduction activities. In con-
trast with most evidence based therapies for PTSD, which focus on processing memories of
traumatic events, the target of NF is neural regulation and stabilization. Since lack of self-regu-
lation has been identified as a principal cause of failure of exposure-based treatments [27–30],
NF may be particularly helpful for traumatized individuals who are too anxious, dissociated or
dysregulated to tolerate exposure based treatments. Finding cost-effective treatments for
PTSD and other psychiatric conditions is particularly important in light of the limitations of
existing treatments. Our results suggest that NF deserves further investigation for its potential
to improve affect regulation, executive functioning and attention.
The former Director of the US National Institutes of Mental Health, calling for the develop-
ment of a next generation of interventions, has noted that four decades of drug development
has resulted in over 20 antipsychotics and over 30 antidepressants that have not demonstrably
reduced the morbidity or mortality of mental disorders [54]. In an emerging new framework
mental disorders are considered to be driven, at least in part, by abnormalities in underlying
neural circuits [55]. A concerted effort is currently underway to map these networks, the so-
called “human connectome project” [56,57]. The fact that mental disorders frequently are
associated with abnormal brain-wave patterns and neural connectivity, including those mea-
sured by the EEG, lends support this approach [58].
Table 3. (Continued)
Variable Condition Pre Mid Pst Pst (1M)
Est. (95%CI) Est. (95%CI) Est. (95%CI) Est. (95%CI)
WL 19.08 (15.83, 22.34) 18.64 (15.78, 21.51) 18.2 (15.36, 21.04) 17.91 (14.87, 20.94)
NF 17.79 (14.73, 20.84) 16.12 (13.41, 18.82) 14.44 (11.71, 17.17) 13.32 (10.37, 16.28)
Difference -1.29 (-5.76, 3.17) -2.53 (-6.47, 1.42) -3.76 (-7.7, 0.18) -4.58 (-8.82, -0.35)
Difference d -0.17 -0.38 -0.56 -0.64
Note: WL = waitlist condition, NF = Neurofeedback condition, Pre = pre-treatment assessment, Pst = immediate post-treatment assessment, Mid = mid-
treatment assessment, Pst (1M) = 1-month post-treatment assessment; M = mean, 95%CI = 95% Confidence Interval, d = effect size indicator with .2, .5,
and .8 indicating small, medium, and large effect sizes.
doi:10.1371/journal.pone.0166752.t003
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Table 4. Change Estimates for Self-Report Measures
Measures
Variable Linear/Ln Change ΔPre-PST effect-size (d) ΔPST-FU effect-size (d)
UCC Model Condition (per week) Pre-Pst Pst-FU
Con x Time Est. (95%CI) Est. (95%CI) Est. (95%CI)
Davidson Trauma Scale (DTS)
Linear WL -0.4 (-0.97, 0.17) -4.76 (-11.6, 2.07) -0.19 -1.59 (-3.87, 0.69) -0.06
Con x Time NF -1.92 (-2.47, -1.37) -23.08 (-29.68, -16.48) -0.92 -7.69 (-9.89, -5.49) -0.31
p< .001 Difference -1.53 (-2.32, -0.74) -18.32 (-27.82, -8.82) -0.73 -6.11 (-9.27, -2.94) -0.24
Difference d -1.16 -0.73 -0.24
IASC interpersonal conflicts
Linear WL -0.07 (-0.23, 0.08) -0.9 (-2.8, 1) -0.15 -0.3 (-0.93, 0.33) -0.05
Con x Time NF -0.16 (-0.31, 0) -1.89 (-3.74, -0.03) -0.32 -0.63 (-1.25, -0.01) -0.11
p = .456 Difference -0.08 (-0.3, 0.14) -0.99 (-3.64, 1.67) -0.17 -0.33 (-1.21, 0.56) -0.06
Difference d -0.23 -0.17 -0.06
IASC tension reduction activities
Natural Log WL 0.2 (-0.51, 0.91) 0.51 (-1.31, 2.32) 0.11 0.05 (-0.14, 0.24) 0.01
Con x Time NF -1.18 (-1.87, -0.49) -3.03 (-4.81, -1.26) -0.64 -0.32 (-0.50, -0.13) -0.07
p = .007 Difference -1.38 (-2.37, -0.39) -3.54 (-6.08, -1.00) -0.75 -0.37 (-0.64, -0.11) -0.08
Difference d -0.86 -0.75 -0.08
IASC affect dysregulation total
Linear WL -0.09 (-0.28, 0.11) -1.02 (-3.36, 1.32) -0.15 -0.34 (-1.12, 0.44) -0.05
Con x Time NF -0.39 (-0.58, -0.2) -4.7 (-6.97, -2.42) -0.67 -1.57 (-2.32, -0.81) -0.22
p = .028 Difference -0.31 (-0.58, -0.03) -3.68 (-6.94, -0.41) -0.53 -1.23 (-2.31, -0.14) -0.18
Difference d -0.68 -0.53 -0.18
IASC affect skill deficits
Linear WL Est. (95%CI) Est. (95%CI) Est. (95%CI)
Con x Time NF -0.05 (-0.17, 0.08) -0.55 (-2.05, 0.96) -0.12 -0.18 (-0.68, 0.32) -0.04
p = .045 Difference -0.22 (-0.35, -0.10) -2.69 (-4.15, -1.23) -0.59 -0.9 (-1.38, -0.41) -0.20
Difference d -0.18 (-0.35, -0.003) -2.14 (-4.24, -0.05) -0.47 -0.71 (-1.41, -0.02) -0.16
-0.63 -0.47 -0.16
IASC affect instability
Linear WL -0.04 (-0.13, 0.05) -0.46 (-1.56, 0.64) -0.14 -0.15 (-0.52, 0.21) -0.05
Con x Time NF -0.16 (-0.25, -0.08) -1.97 (-3.04, -0.90) -0.58 -0.66 (-1.01, -0.30) -0.19
p = .053 Difference -0.13 (-0.25, 0.001) -1.51 (-3.04, 0.02) -0.45 -0.5 (-1.01, 0.01) -0.15
Difference d -0.60 -0.45 -0.15
IASC identity impairment total
Linear WL -0.04 (-0.25, 0.16) -0.50 (-2.97, 1.96) -0.06 -0.17 (-0.99, 0.65) -0.02
Con x Time NF -0.28 (-0.48, -0.07) -3.30 (-5.72, -0.88) -0.41 -1.10 (-1.91, -0.29) -0.14
p = .110 Difference -0.23 (-0.52, 0.05) -2.80 (-6.25, 0.66) -0.35 -0.93 (-2.08, 0.22) -0.12
Difference d -0.51 -0.35 -0.12
IASC idealization-disillusionment
Linear WL -0.01 (-0.18, 0.15) -0.14 (-2.12, 1.83) -0.02 -0.05 (-0.71, 0.61) -0.01
Con x Time NF -0.2 (-0.36, -0.04) -2.39 (-4.32, -0.46) -0.35 -0.8 (-1.44, -0.15) -0.12
p = .109 Difference -0.19 (-0.42, 0.04) -2.24 (-5.01, 0.52) -0.33 -0.75 (-1.67, 0.17) -0.11
Difference d -0.50 -0.33 -0.11
IASC abandonment concerns
Natural Log WL -0.05 (-1.19, 1.09) -0.13 (-3.05, 2.79) -0.02 -0.01 (-0.32, 0.29) 0.00
Con x Time NF -1.72 (-2.84, -0.60) -4.42 (-7.28, -1.55) -0.59 -0.46 (-0.76, -0.16) -0.06
(Continued )
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Neurofeedback is a promising change agent for habitual dysfunctional neuronal patterns.
The vast potential of EEG. based brain-computer interface techniques to train neuronal pat-
terns is illustrated by recent research at the University of Minnesota. Using advanced func-
tional neuroimaging including BOLD functional fMRI and EEG source imaging, they trained
normal research subjects to control the flight of a virtual helicopter in 3-dimensional space
through an obstacle course, based only upon motor imagination [59]. The equipment used in
our study was much less sophisticated than that used in the helicopter navigation study, but it
cost less than $10,000. If further research confirms the results from our study, neurofeedback
has the potential of becoming widely available in community settings since can be economi-
cally administered by well-trained technicians in small offices and clinics.
Limitations
There are major limitations in this relatively small, non-placebo controlled study, including: 1)
This study employed a waitlist control group that received TAU (psychotherapy + medica-
tions). While this is an appropriate control, findings would be more robust with a sham con-
trol condition; 2) This study only had a one-month follow up. Further studies are needed to
establish the relative permanency of NF generated clinical improvements and investigate the
necessity for follow-up booster sessions. 3) In this study we used clinical indications- PTSD
symptoms- to guide our approach. It remains to be determined whether it is optimal to target
specific abnormalities in brain EEG patterns, or clinical symptomatology in NF research. 4)
This study did not examine to what degree clinical changes are correlated with specific alter-
ations in EEG, or other neural activation patterns. 5) The NF protocol targeted R temporal
lobe EEG patterns. Future research need to determine the optimal targets and procedures for
the treatment of PTSD and other clinical conditions, including whether there are optimal pro-
tocols for different clinical conditions, or whether psychiatric patients are best served by indi-
vidualized targeted interventions that use advanced EEG imaging technologies such as
sLORETA [60].
Table 4. (Continued)
Measures
Variable Linear/Ln Change ΔPre-PST effect-size (d) ΔPST-FU effect-size (d)
UCC Model Condition (per week) Pre-Pst Pst-FU
Con x Time Est. (95%CI) Est. (95%CI) Est. (95%CI)
p = .041 Difference -1.67 (-3.27, -0.07) -4.29 (-8.38, -0.19) -0.57 -0.45 (-0.88, -0.02) -0.06
Difference d -0.62 -0.57 -0.06
IASC susceptibility to influence
Linear WL -0.07 (-0.25, 0.10) -0.88 (-3.00, 1.23) -0.12 -0.29 (-1.00, 0.41) -0.04
Con x Time NF -0.28 (-0.45, -0.11) -3.35 (-5.41, -1.29) -0.44 -1.12 (-1.80, -0.43) -0.15
p = .099 Difference -0.21 (-0.45, 0.04) -2.47 (-5.42, 0.49) -0.33 -0.82 (-1.81, 0.16) -0.11
Difference d -0.51 -0.33 -0.11
Note: WL = waitlist condition, NF = Neurofeedback condition, Est. = estimate, 95%CI = 95% Confidence Interval, d = effect size indicator with .2, .5, and .8
indicating small, medium, and large effect sizes, ΔPre-Pst(1M) = the estimate of total change from the pre-treatment to the 1-month post-treatment
assessment, NA = Not Applicable (there is not quadratic estimate for linear and natural-log change models). The far left column denotes the outcome
(underlined), the unconditional model (UCC) that best fit the data (linear, quadratic, or natural log), and the significance of the overall time x condition
interaction (con x time). Z–because quadratic change models involve two change parameters (linear, quadratic) the 95% confidence intervals for these
models could not be calculated.
doi:10.1371/journal.pone.0166752.t004
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Finally, the power analysis indicated that the study was slightly underpowered. There are
two primary problems with underpowered studies: 1) increased risk of Type II errors, and 2)
insufficient sample to produce unbiased or stable parameter estimates. Regarding #1, the cur-
rent study produced hypothesized statistically significant effects ruling out Type II error.
Regarding #2, the Monte Carlo procedure used for the power analysis produced estimates of
0.1%, 4.8%, and 92.6% for parameter estimate bias, standard error bias, and coverage, respec-
tively, for the condition x time interaction for the CAPS, and 0.04%, 5.05,% and 93.5% for the
DTS power. As per criteria specified by Muthe´n and Muthe´n [46] these values suggest that the
sample size for the current study produced unbiased and stable estimates. The current study
produced statistically significant effects despite being underpowered, which mitigates concerns
that have been expressed regarding the use of post-hoc power analysis to argue that the results
of negative trials may be meaningful despite the failure to detect significant effects due to being
underpowered (e.g., [61]). The current study used post-hoc analysis to investigate the stability
of the produced coefficients, and we followed recommendations of those who caution against
the use of post-hoc test to report confidence intervals for coefficients.
Future directions
This study suggests that BCIs may have similar clinical potential for psychiatry as they do for
rehabilitation medicine. Further clinical trials are needed to further substantiate to what degree
BCIs can improve attention and affect regulation, and enhance cognitive performance and
executive functioning. Using a combination of fMRI and quantitative EEG technology to
define neural circuitry abnormalities, and studying the capacity of targeted neurofeedback
interventions to alter these circuits would be a major step in that direction (e.g.11). Clarifying
to what degree NF induced psychological changes are correlated with specific changes in neu-
ral activity will be a complex scientific challenge akin to correlating the clinical effects of vari-
ous psychiatric medications with specific neurochemical changes in the brain.
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